By Adriano Marchese
Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials.
The clinical-stage biopharmaceutical company said Wednesday that it has voluntarily halted all dosing in the phase 2 Tropos trial for the drug cibotercept, which aims to treat pulmonary arterial hypertension.
The decision was made after new observations of pericardial effusion in patients, an adverse effect in which excess fluid builds up around the heart.
Keros said the trial is being terminated early, but that it will continue to monitor its patients. The company continues to expect to present its findings in the second quarter.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 15, 2025 06:51 ET (11:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.